||||||||||Stivarga (regorafenib) / Bayer ANGIOPOIETIN-2 EARLY INCREASE PREDICTS BENEFIT FROM REGORAFENIB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS: THE PROSPECTIVE REGOLAND STUDY ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_161; Ang-2 is a prognostic marker and its early modulation predicts clinical benefit among mCRC patients treated with regorafenib. We hypothesize that Ang-2 levels early increase as a consequence of the successful inhibition of Tie-2 by regorafenib that leads to a compensatory increase of the ligand and correlates with anti-tumour activity.